Skip to content

Home
About Us
- Board of Directors
- Management Team
Technology
News/Resources
Investor Centre
Contacts

ASX Announcements 2024

15 Nov 2024
Revised Continuous Disclosure Policy
30 Oct 2024
Quarterly Report 30 September 2024
30 Oct 2024
Report on Activities for the Quarter Ended 30 September 2024
14 Oct 2024
R&D Tax Incentive
25 Sep 2024
Biotron Response to ASX Aware Query
6 Sep 2024
BIT225-012 Phase 2 COVID-19 Clinical Trial
30 Aug 2024
Corporate Governance Statement 2024
30 Aug 2024
Appendix 4G
30 Aug 2024
Year End Accounts and Preliminary Final Report
31 Jul 2024
Quarterly Report 30 June 2024
31 Jul 2024
Report on Activities for the Quarter Ended 30 June 2024
11 Jul 2024
Shareholder Update
25 Jun 2024
Biotron Clinical Trial Results Webinar
19 Jun 2024
BIT225-011 Phase 2 HIV Exploratory Efficacy Trial Meets Primary Objectives
24 May 2024
Change of Registry Address Notification
26 Apr 2024
Quarterly Report 31 March 2024
26 Apr 2024
Report on Activities for the Quarter Ended 31 March 2024
5 Apr 2024
Positive Outcomes in BIT225 Phase 2 Clinical Trial in HIV (BIT225-010)
27 Feb 2024
Half-year Report 31 December 2023
8 Feb 2024
R&D Tax Incentive
30 Jan 2024
Report on Activities for the Quarter Ended 31 December 2023
30 Jan 2024
Quarterly Report 31 December 2023

2024
2023

2022

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
>>

Investor Centre

Investor Centre

© Biotron Limited 2016 ABN 60 086 399 144 Site updated 15 November 2024 Legal Notices and Privacy